|
Home:
Educational
Supplement: Section 5
SELECT PUBLICATIONS
Bajetta E et
al. Aromatase inhibitors in the treatment of postmenopausal breast
cancer. Drugs Aging 1999;15:271-83. Abstract
Blankenstein
MA et al. Intratumoral levels of estrogens in breast cancer.
J Steroid Biochem Mol Biol 1999;69:293-7. Abstract
Brodie AM,
Njar VC. Aromatase inhibitors and their application in breast
cancer treatment. Steroids 2000;65:171-9. Abstract
Crucitta E
et al. New aromatase inhibitors in the treatment of advanced
breast cancer. Int J Oncol 2000;17:1037-41. Abstract
Dixon JM et
al. Lessons from the use of aromatase inhibitors in the neoadjuvant
setting. Endocrine-Related Cancer 1999;6(2):227-230.
Full-Text
Dixon JM et
al. The effects of neoadjuvant anastrozole (Arimidex) on tumor
volume in postmenopausal women with breast cancer: A randomized,
double-blind, single-center study. Clin Cancer Res 2000;6(6):2229-35.
Abstract
Dowsett M.
Drug and hormone interactions of aromatase inhibitors. Endocr
Relat Cancer 1999;6:181-5. Full-Text
Dowsett M et
al. Effects of the aromatase inhibitor anastrozole on serum oestrogens
in Japanese and Caucasian women. Cancer Chemother Pharmacol
2000;46:35-9. Abstract
Dowsett M et
al. Impact of tamoxifen on the pharmacokinetics and endocrine
effects of the aromatase inhibitor letrozole in postmenopausal women
with breast cancer. Clin Cancer Res 1999;5:2338-43. Abstract
Ellis MJ et
al. Letrozole (Femara) is a more effective inhibitor of estrogen
activity than tamoxifen: Evidence from a randomized phase III trial
of 4 months preoperative endocrine therapy for postmenopausal women
with primary invasive breast cancer. Proc ASCO 2001;Abstract
1661.
Esparza-Guerra
L, Buzdar A. Anastrozole 'Arimidex' does not impair adrenal cortisol
or aldosterone synthesis in postmenopausal women with advanced breast
cancer. Proc ASCO 2001;Abstract
1954.
Geisler J et
al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral
estrogen levels and proliferation markers in patients with locally
advanced breast cancer. Clin Cancer Res 2001;7(5):1230- 6.
Abstract
Goss PE. Risks
versus benefits in the clinical application of aromatase inhibitors.
Endocr Relat Cancer 1999;6:325-32. Full-Text
Harper-Wynne
C, Dowsett M. Recent advances in the clinical application of
aromatase inhibitors. J Steroid Biochem Mol Biol 2001;76:179-86.
Abstract
Higa GM. Altering
the estrogenic milieu of breast cancer with a focus on the new aromatase
inhibitors. Pharmacotherapy 2000;20:280- 91. Abstract
Higa GM. New
generation aromatase inhibitors in breast cancer. Weighing out potential
costs and benefits. Pharmacoeconomics 2000;17:121-32.
Abstract
Howell A. The
Anastrozole, Tamoxifen, Alone or in Combination (ATAC) adjuvant
breast cancer trial in postmenopausal women: Regional variation
in knowledge of hormone receptor status prior to randomisation into
the trial. The ATAC Trialists Group. Ann Oncol 2000;11(Suppl
4):Abstract
76.
Lonning PE.
Clinico-pharmacological aspects of different hormone treatments.
Eur J Cancer 2000;36 Suppl 4:S81-2. Abstract
Lonning PE.
Is there a growing role for endocrine therapy in the treatment
of breast cancer? Drugs 2000;60:11-21. Abstract
Michaud LB,
Buzdar AU. Risks and benefits of aromatase inhibitors in postmenopausal
breast cancer. Drug Saf 1999;21:297-309. Abstract
Miles I et
al. Neoadjuvant Arimidex or tamoxifen, alone or combined, for
breast cancer (IMPACT): PgR-related reductions in proliferation
marker KI67. Proc ASCO 2000;Abstract
360.
Mouridsen H
et al. Superior efficacy of letrozole versus tamoxifen as first-line
therapy for postmenopausal women with advanced breast cancer: Results
of a phase III study of the International Letrozole Breast Cancer
Group. J Clin Oncol 2001:2596-2606. Abstract
Muss HB. New
Hormonal Therapies for Breast Cancer. Cancer Control 1999;6:247-255.
Full-Text
Nabholtz JM
et al. Anastrozole is superior to tamoxifen as first-line therapy
for advanced breast cancer in postmenopausal women: Results of a
North American multicenter randomized trial. J Clin Oncol
2000;18(22):3758-3767. Abstract
Njar VC, Brodie
AM. Comprehensive pharmacology and clinical efficacy of aromatase
inhibitors. Drugs 1999;58:233-55. Abstract
Ragaz J. Status
of aromatase inhibitors in relation to other breast cancer treatment
modalities. Endocr Relat Cancer 1999;6:277-91. Full-Text
Sainsbury R.
The Anastrozole, Tamoxifen, Alone or in Combination (ATAC) adjuvant
breast cancer trial in postmenopausal women: Regional variations
in surgical practice in patients recruited into the trial. The
ATAC Trialists Group. Ann Oncol 2000;11(Suppl 4):Abstract
78. Sasano
H et al. Effects of aromatase inhibitors on the pathobiology
of the human breast, endometrial and ovarian carcinoma. Endocr
Relat Cancer1999;6:197-204. Full-Text
Scott LJ, Wiseman
LR. Exemestane. Drugs 1999;58:675-80; discussion 681-2. Abstract
Smith IE. Aromatase
inhibitors: A dose-response effect? Endocr Relat Cancer 1999;6:245-9.
Full-Text
Trialists'
Group TA. Pharmacokinetics of anastrozole and tamoxifen alone
and in combination during adjuvant endocrine therapy for early breast
cancer in postmenopausal women: A subprotocol of the 'Arimidex®
and Tamoxifen Alone or in Combination' (ATAC)trial. Br J Cancer
2001;85(3):317-24. Abstract
Venturino A
et al. Formestane is feasible and effective in elderly breast
cancer patients with comorbidity and disability. Breast Cancer
Res Treat 2000;62:217-22. Abstract
Top
Additional
Sections:
1 | 2
| 3 | 4
| 5 | 6
| 7 | 8
| 9 | 10
| 11 | 12
|
|
